1. Home
  2. STKS vs ACET Comparison

STKS vs ACET Comparison

Compare STKS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

N/A

Current Price

$1.80

Market Cap

74.3M

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.20

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKS
ACET
Founded
2004
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.3M
69.6M
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
STKS
ACET
Price
$1.80
$7.20
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$4.50
$56.00
AVG Volume (30 Days)
27.0K
110.8K
Earning Date
06-15-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$673,344,000.00
N/A
Revenue This Year
$23.94
N/A
Revenue Next Year
$5.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
102.35
N/A
52 Week Low
$1.70
$0.45
52 Week High
$5.19
$9.05

Technical Indicators

Market Signals
Indicator
STKS
ACET
Relative Strength Index (RSI) 39.62 48.87
Support Level $1.70 $6.54
Resistance Level $2.08 $8.34
Average True Range (ATR) 0.14 0.46
MACD -0.02 -0.05
Stochastic Oscillator 13.58 31.72

Price Performance

Historical Comparison
STKS
ACET

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: